{
  "guideline": {
    "id": "PA166211021",
    "name": "Annotation of DPWG Guideline for siponimod and CYP2C9",
    "objCls": "Guideline Annotation",
    "source": "DPWG",
    "version": 9,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166211021",
    "relatedChemicals": [
      {
        "id": "PA166182736",
        "name": "siponimod",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299159",
      "name": "Recommendation PA166299159",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061522,
        "html": "<p>Avoid siponimod.</p>\n"
      },
      "implications": [
        "Siponimod is contraindicated in patients with this genetic variation. Theoretically, the risk of adverse effects is greatly increased, as the genetic variation results in much higher plasma concentrations of siponimod."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*3": 2.0
        }
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299155",
      "name": "Recommendation PA166299155",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061518,
        "html": "<p>Avoid siponimod.</p>\n"
      },
      "implications": [
        "Siponimod is contraindicated in patients with the comparable genetic variation *3/*3. Theoretically, the risk of adverse effects is greatly increased, as the genetic variation results in much higher plasma concentrations of siponimod."
      ],
      "lookupKey": {
        "CYP2C9": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299158",
      "name": "Recommendation PA166299158",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061521,
        "html": "<p>Use 50% of the normal maintenance dose. Reconsider the choice and the potential benefit of siponimod if the patient is also using a moderate CYP3A4 inducer, such as modafinil. For this genetic variation, a moderate CYP3A4 inducer results in a reduction in the exposure of siponimod by 49%, according to a pharmacokinetic model.</p>\n"
      },
      "implications": [
        "Theoretically, the risk of adverse effects in increased, as the genetic variation results in higher plasma concentrations of siponimod."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*2": 1.0,
          "*3": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299153",
      "name": "Recommendation PA166299153",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061516,
        "html": "<p>Use 50% of the normal maintenance dose. Reconsider the choice and the potential benefit of siponimod if the patient is also using a moderate CYP3A4 inducer, such as modafinil. For the comparable genetic variation *1/*3, the moderate CYP3A4 inducer results in a reduction in the exposure of siponimod by 49%, according to a pharmacokinetic model.</p>\n"
      },
      "implications": [
        "Theoretically, the risk of adverse effects in increased, as the genetic variation results in higher plasma concentrations of siponimod."
      ],
      "lookupKey": {
        "CYP2C9": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299156",
      "name": "Recommendation PA166299156",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061519,
        "html": "<p>Use 50% of the normal maintenance dose. Reconsider the choice and the potential benefit of siponimod if the patient is also using a moderate CYP3A4 inducer, such as modafinil. For this genetic variation, a moderate CYP3A4 inducer results in a reduction in the exposure of siponimod by 49%, according to a pharmacokinetic model.</p>\n"
      },
      "implications": [
        "Theoretically, the risk of adverse effects in increased, as the genetic variation results in higher plasma concentrations of siponimod."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*3": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299152",
      "name": "Recommendation PA166299152",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061515,
        "html": "<p>The guideline does not provide a recommendation for siponimod in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on siponimod."
      ],
      "lookupKey": {
        "CYP2C9": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299157",
      "name": "Recommendation PA166299157",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061520,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The genetic variation can slightly increase the exposure to siponimod. However, the effect is too small to expect any impact on efficacy or adverse effects."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*2": 2.0
        }
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299154",
      "name": "Recommendation PA166299154",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061517,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The genetic variation can slightly increase the exposure to siponimod. However, the effect is too small to expect any impact on efficacy or adverse effects."
      ],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*2": 1.0
        }
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}